Torasemide

Cardiovascular and cerebrovascular diseases such as chronic heart failure and hypertension have become the leading causes of death worldwide, and the clinical demand for diuretics with high efficacy and low side effects has been strong for a long time. Torasemide is a new generation of loop diuretic. It reduces electrolyte reabsorption by inhibiting the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the medullary loop. Compared with traditional furosemide, it has the advantages of high bioavailability, long duration of action and low risk of potassium loss. At present, it is widely used in the treatment of edema caused by congestive heart failure and essential hypertension, and is the preferred diuretic category for patients with renal impairment combined with heart failure.

The global torasemide market size was approximately USD 1.28 billion in 2023, and is expected to grow at a compound annual growth rate of 4.2% to USD 1.57 billion by 2028. The core growth drivers are the continuous rise in the global prevalence of heart failure and the increasing penetration rate of long-acting diuretics in the primary market. In terms of the domestic market, torasemide has been included in the National Medical Insurance Category A Catalog. In 2023, the terminal sales in domestic public medical institutions exceeded RMB 1.8 billion. At present, the market is dominated by generic drugs, and local enterprises account for more than 85% of the market share, among which there are more than 30 preparation manufacturers, and the supply and demand gap for compliant and high-quality API has existed for a long time.

The original developer of torasemide is Boehringer Mannheim, Germany (later acquired by Roche), with the original brand name "Demadex", and its core compound patent expired worldwide in 2003. The main dosage forms approved for the original drug include tablets (2.5mg, 5mg, 10mg, 20mg) and injections (10mg/1ml, 20mg/2ml), which have been included in the FDA Reference Listed Drug Catalog and the Chinese *Catalog of Reference Preparations for Chemical Drugs*. At present, more than 20 domestic enterprises have obtained CDE registration (status A) for torasemide API. The preparations approved for marketing cover three categories: tablets, capsules and injections, and 15 preparation enterprises have passed the consistency evaluation. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for torasemide API, which comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations. Most impurities are in stock, and orders placed before 16:00 can be shipped on the same day, which can quickly meet the needs of API manufacturers and R&D institutions in impurity research, quality control and other scenarios.